Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Read More →
Tofacent 5 Mg (Tofacitinib)
Disclaimer: Before purchasing any medicine, always verify whether there is a valid drug license.
Tofacent 5 mg is identified on this website as a product containing tofacitinib 5 mg, an orally administered small-molecule Janus kinase (JAK) inhibitor. The specific manufacturer, marketing authorization holder, manufacturing site, formulation, packaging, country-specific registration and regulatory status of the Tofacent-branded product should be verified against the actual product packaging and official product documentation before publication.
Tofacitinib is an immunomodulatory medicine that inhibits JAK-dependent intracellular signaling involved in inflammatory and immune responses. The established U.S. reference product is XELJANZ, developed by Pfizer. Pfizer states that its scientists discovered and developed XELJANZ/tofacitinib, and the U.S. Food and Drug Administration granted the original approval in 2012.
The supplied website material should therefore distinguish clearly between Tofacent as the specific branded product and tofacitinib as the active pharmaceutical ingredient. Tofacent should not automatically be described as identical to XELJANZ without product-specific evidence.
Incepta Pharmaceuticals Ltd. About the Manufacturer
Incepta Pharmaceuticals Ltd. is a leading pharmaceutical manufacturer in Bangladesh, established in 1999. The company develops and manufactures a wide range of pharmaceutical products for the domestic and international markets. Its major manufacturing facilities are located in Savar and Dhamrai, Bangladesh.
Incepta manufactures different dosage forms, including tablets, capsules, oral liquids, injections, eye drops, creams, ointments, gels, nasal sprays, prefilled syringes, lyophilized injections, and biological products. The company also focuses on technologically advanced dosage forms and pharmaceutical research and development.
Address: Incepta Pharmaceuticals Ltd. 40 Shahid Tajuddin Ahmed Sarani, Tejgaon I/A, Dhaka-1208, Bangladesh
What Is Tofacent 5 mg?
Tofacent 5 mg is identified for this website as a tofacitinib-containing product. Tofacitinib is a targeted immunomodulatory medicine belonging to the JAK inhibitor class.
JAK enzymes participate in signaling pathways used by numerous cytokines and growth factors. By inhibiting JAK signaling, tofacitinib reduces signaling involved in inflammatory and immune-system activity.
The specific clinical use of a Tofacent product must be determined from its applicable regulatory authorization and prescribing information. The presence of tofacitinib as an active ingredient does not by itself establish that every indication approved for XELJANZ is authorized for Tofacent in every country.
What Is Tofacitinib?
Tofacitinib is a small-molecule Janus kinase inhibitor. Unlike biologic medicines that generally act outside cells or bind extracellular targets, tofacitinib works on intracellular signaling pathways.
Pfizer developed tofacitinib as CP-690,550 and subsequently developed it as XELJANZ. Pfizer’s historical materials describe XELJANZ as the first approved rheumatoid arthritis treatment in the JAK-inhibitor class.
The original U.S. approval of XELJANZ was for adults with moderately to severely active rheumatoid arthritis who had an inadequate response or intolerance to methotrexate.
Current U.S. labeling has subsequently expanded to include additional immune-mediated conditions.
Originator, Reference Product and First Manufacturer
Who developed tofacitinib?
Pfizer discovered and developed tofacitinib. Pfizer’s announcement concerning the 2012 FDA approval specifically states that the discovery and development of XELJANZ were carried out by Pfizer scientists.
The medicine was developed under the research code CP-690,550 before becoming associated with the commercial brand XELJANZ.
What is the reference product?
The established U.S. reference brand is:
XELJANZ® (tofacitinib)
XELJANZ received its initial U.S. approval in November 2012. The original FDA label records an initial U.S. approval of 2012.
Who first manufactured it?
Pfizer was the company responsible for the original development and commercialization of XELJANZ. The original FDA label identifies Pfizer’s U.S. organization in the product information and states that the product was distributed by Pfizer Labs, Division of Pfizer Inc.
For website wording, it is preferable to state:
Tofacitinib was discovered and developed by Pfizer, and the original reference medicine was XELJANZ. The specific manufacturing entity and manufacturing site associated with the original commercial product should be described according to the applicable historical regulatory documentation rather than assumed solely from the Pfizer brand name.
This distinction is important because originator/developer, manufacturer, marketing authorization holder, brand owner and distributor are not necessarily the same legal entity.
Tofacent and XELJANZ: Are They the Same?
Tofacent and XELJANZ should not automatically be described as identical products merely because both are identified as containing tofacitinib.
They may differ in:
- Manufacturer
- Marketing authorization holder
- Manufacturing site
- Excipients
- Tablet formulation
- Packaging
- Country-specific authorization
- Regulatory pathway
- Commercial supply chain
- Product labeling
The active pharmaceutical ingredient may be the same, but product-specific equivalence and authorization should be established through appropriate regulatory and pharmaceutical documentation.
How Tofacitinib Works
Tofacitinib inhibits Janus kinase enzymes, which are intracellular enzymes involved in signaling from multiple cytokine receptors.
The JAK family includes:
- JAK1
- JAK2
- JAK3
- TYK2
Tofacitinib has particular activity against JAK1 and JAK3 and, to a lesser extent, JAK2. The resulting reduction in cytokine signaling can decrease inflammatory and immune-system activity.
Simple explanation
In simple terms, tofacitinib works by interfering with intracellular communication signals that immune cells use to produce and maintain inflammation.
This mechanism can help reduce inflammatory activity in selected immune-mediated diseases, but the same immunomodulatory effect can also increase susceptibility to infections and contribute to other clinically important risks.
What Is Tofacitinib Used For?
Approved uses depend on the product, formulation, patient population and regulatory jurisdiction.
Current U.S. labeling for tofacitinib tablets includes adult patients with:
- Moderately to severely active rheumatoid arthritis
- Active psoriatic arthritis
- Active ankylosing spondylitis
- Moderately to severely active ulcerative colitis
The current U.S. labeling also includes certain pediatric patients aged 2 years and older with active psoriatic arthritis or polyarticular-course juvenile idiopathic arthritis.
The applicable indication generally involves patients who have had an inadequate response or intolerance to one or more TNF blockers under current U.S. labeling.
Important jurisdictional limitation
These indications should not automatically be presented as approved indications for Tofacent.
The authorization of a specific Tofacent product must be confirmed through its applicable national or regional regulatory documentation.
Rheumatoid Arthritis
Tofacitinib is used in selected adults with moderately to severely active rheumatoid arthritis.
Rheumatoid arthritis is a chronic inflammatory autoimmune disease in which abnormal immune activity contributes to inflammation of the joints and can cause progressive structural damage.
The original U.S. XELJANZ approval in 2012 was for adults with moderately to severely active rheumatoid arthritis who had an inadequate response or intolerance to methotrexate.
Current U.S. labeling contains updated requirements concerning previous treatment and TNF-blocker response.
Psoriatic Arthritis
Tofacitinib is also authorized in the United States for selected adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
Psoriatic arthritis is an inflammatory arthritis associated with psoriasis and can affect peripheral joints, the spine, entheses and other structures.
Ankylosing Spondylitis
Current U.S. labeling includes tofacitinib for selected adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers.
Ankylosing spondylitis is a chronic inflammatory disease that primarily affects the axial skeleton and can cause pain and stiffness.
Ulcerative Colitis
Tofacitinib is also used in selected adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers under current U.S. labeling.
Ulcerative colitis is an inflammatory bowel disease affecting the lining of the colon and rectum.
Pediatric Uses
Current U.S. labeling includes certain pediatric patients aged 2 years and older with:
- Active psoriatic arthritis after inadequate response or intolerance to one or more TNF blockers
- Active polyarticular-course juvenile idiopathic arthritis after inadequate response or intolerance to one or more TNF blockers
The precise pediatric formulation and dosage must be determined from the applicable official product labeling.
Tofacent 5 mg Dosage Information
A product described as Tofacent 5 mg contains a stated 5 mg strength, but the appropriate dosing schedule cannot be determined from the product name alone.
Tofacitinib dosing depends on:
- Disease being treated
- Patient age
- Formulation
- Treatment response
- Kidney function
- Liver function
- Concomitant medicines
- Infection risk
- Other clinical factors
- Applicable regulatory labeling
The original XELJANZ approval used 5 mg twice daily for the original rheumatoid arthritis indication.
However, the current prescribing information contains indication-specific and patient-specific dosing recommendations. Therefore, a website should not present 5 mg as a universal dosing schedule for every tofacitinib patient.
Do not start, stop, increase or decrease tofacitinib without professional medical guidance.
How to Take Tofacitinib
Tofacitinib is an oral medicine.
Depending on the formulation and prescription, it may be administered according to a regular daily or twice-daily regimen. The exact administration instructions should be taken from the applicable prescribing information for the particular product.
General principles include:
- Take the medicine exactly as prescribed.
- Do not take more than the prescribed amount.
- Do not change the dosing frequency independently.
- Do not stop treatment without discussing it with the treating healthcare professional.
- Follow the instructions specific to the formulation supplied.
- Keep the medicine in its original labeled packaging unless otherwise instructed.
For Tofacent specifically, administration instructions should be verified against the actual product documentation.
Missed Dose
If a dose is missed, patients should follow the instructions in the applicable product information or contact their healthcare professional or pharmacist.
Patients should not routinely compensate for a missed dose by taking an additional dose unless specifically instructed to do so.
Important Safety Information
Tofacitinib carries significant safety warnings.
The current U.S. XELJANZ prescribing information contains a boxed warning concerning:
- Serious infections
- Mortality
- Malignancy
- Major adverse cardiovascular events
- Thrombosis
These risks are clinically important and require appropriate patient selection and monitoring.
Serious Infections
Tofacitinib can increase the risk of serious bacterial, fungal, viral and opportunistic infections, including tuberculosis.
Serious infections may result in hospitalization or death. Current labeling recommends evaluation for latent tuberculosis before treatment and monitoring for active tuberculosis during treatment.
Patients should promptly report symptoms that could indicate an infection.
Mortality Risk
The current U.S. boxed warning identifies an increased risk of all-cause mortality, including sudden cardiovascular death, in the studied rheumatoid arthritis population compared with TNF blockers.
This risk is particularly important when assessing whether tofacitinib is appropriate for individual patients.
Malignancy
Malignancies have occurred in patients treated with tofacitinib.
The current U.S. labeling identifies a higher rate of lymphoma and lung cancer with XELJANZ compared with TNF blockers in the studied rheumatoid arthritis population.
Patient-specific cancer risk factors should be considered by the treating healthcare professional.
Major Cardiovascular Events
Major adverse cardiovascular events, including cardiovascular death, myocardial infarction and stroke, are included in the boxed warning.
The current U.S. labeling reports a higher rate of major adverse cardiovascular events with XELJANZ compared with TNF blockers in the studied rheumatoid arthritis population.
Thrombosis
Thrombosis is another major safety concern.
Reported events include:
- Pulmonary embolism
- Deep-vein thrombosis
- Arterial thrombosis
Some events have been serious or fatal. Current labeling identifies an increased incidence of pulmonary embolism and venous and arterial thrombosis with XELJANZ compared with TNF blockers in the relevant rheumatoid arthritis population.
Other Important Safety Considerations
Tofacitinib labeling also addresses:
- Gastrointestinal perforation
- Hypersensitivity reactions
- Laboratory abnormalities
- Changes in blood counts
- Lipid abnormalities
- Liver-enzyme abnormalities
- Vaccination considerations
- Hypoglycemia in certain patients with diabetes
- Formulation-specific gastrointestinal obstruction risk for XELJANZ XR
The complete prescribing information should be consulted for the full warnings and precautions.
Tuberculosis and Infection Screening
Before and during treatment, clinicians may evaluate patients for:
- Tuberculosis
- Viral hepatitis
- Other active infections
- Relevant vaccination status
Treatment may need to be interrupted if a serious infection develops.
The exact screening and monitoring program should be determined by the treating healthcare professional and applicable prescribing information.
Laboratory Monitoring
Tofacitinib treatment can require laboratory monitoring.
Depending on the patient and indication, monitoring may include:
- Complete blood count
- Neutrophil count
- Lymphocyte count
- Hemoglobin
- Liver enzymes
- Lipid profile
- Kidney function
- Infection assessment
The frequency of monitoring depends on clinical circumstances and the applicable product information.
Vaccination Considerations
Vaccination status should be reviewed before treatment when appropriate.
Because tofacitinib affects immune-system function, vaccination decisions should be discussed with a healthcare professional.
Patients should not independently receive or avoid a particular vaccine solely on the basis of website information.
Pregnancy and Breastfeeding
Tofacitinib has clinically important considerations concerning pregnancy and lactation.
The current U.S. XELJANZ labeling advises against breastfeeding during treatment.
Patients who are pregnant, planning pregnancy or breastfeeding should discuss treatment with their healthcare professional before using tofacitinib.
Drug Interactions
Tofacitinib can interact with other medicines.
Particular attention may be required when tofacitinib is combined with:
- Strong CYP3A4 inhibitors
- Medicines affecting CYP pathways
- Immunosuppressive medicines
- Biologic DMARDs
- Potent immunosuppressants
Current U.S. labeling does not recommend combining tofacitinib for its inflammatory indications with biologic DMARDs or potent immunosuppressants such as azathioprine or cyclosporine.
Patients should provide their healthcare professional with a complete list of prescription medicines, over-the-counter products and supplements.
Commonly Reported Adverse Reactions
Adverse reactions vary according to the indication and treatment population.
Reported reactions with tofacitinib include conditions such as:
- Upper respiratory tract infections
- Nasopharyngitis
- Headache
- Diarrhea
- Nausea
- Increased cholesterol levels
- Herpes zoster
- Rash
- Increased creatine phosphokinase
The frequency and clinical importance of individual adverse reactions vary between indications and studies.
A single adverse-effect frequency table should therefore not be generalized to every patient taking Tofacent.
When to Seek Medical Attention
Prompt medical evaluation may be appropriate for symptoms such as:
- Severe or persistent fever
- Signs of serious infection
- Chest pain
- Sudden shortness of breath
- Coughing blood
- Sudden weakness or neurological symptoms
- Severe leg swelling or pain
- Symptoms suggesting a blood clot
- Severe allergic reactions
- Severe abdominal pain
- Other unusual or rapidly worsening symptoms
These symptoms can have multiple causes, and urgent assessment may be required.
Clinical Pharmacology
Tofacitinib is a small-molecule JAK inhibitor.
Its pharmacological activity results from inhibition of JAK-mediated signaling pathways used by cytokines involved in immune and inflammatory responses.
Because JAK pathways participate in normal immune function as well as disease-related inflammation, pharmacological inhibition can produce both therapeutic effects and clinically important immunosuppressive risks.
Reference Product History
XELJANZ
XELJANZ (tofacitinib) is the established reference brand associated with the original development and U.S. approval of tofacitinib.
Pfizer announced FDA approval of XELJANZ in November 2012 for adults with moderately to severely active rheumatoid arthritis who had an inadequate response or intolerance to methotrexate.
Pfizer’s historical materials describe XELJANZ as the first approved rheumatoid arthritis treatment in the JAK-inhibitor class.
The original FDA labeling identified the product as XELJANZ (tofacitinib) tablets for oral use, with a 5 mg strength.
Incepta Pharmaceuticals Ltd. Verification Process
Scan the QR code printed on the product box. The QR code will take you to the official Incepta product verification page, where you can complete the verification process.
The QR code will direct you to the Incepta Pharmaceuticals Ltd. e-verification page, where you can complete the product verification process.
After completing the verification, check the result carefully to confirm whether the product is genuine.
If the verification indicates that the product is fake or unauthorized, do not use it. Report the suspected counterfeit product and take appropriate legal action against the supplier through the Directorate Incepta of Drug Administration (DGDA), World.
Always purchase medicines from licensed pharmacies or authorized suppliers and verify the product before use.
Manufacturer vs. Originator vs. Marketing Authorization Holder
These terms have different meanings.
| Term | Meaning |
| Originator/developer | Company that discovered and developed the medicine |
| Reference-product company | Company associated with the reference medicinal product |
| Manufacturer | Entity responsible for manufacturing the specific product |
| Marketing authorization holder | Entity legally responsible for the product authorization in a jurisdiction |
| Brand owner | Entity controlling the commercial brand |
| Distributor | Entity involved in distribution |
| Supplier | Entity supplying the product through a particular channel |
For Tofacent, these identities should not be treated as interchangeable.
Storage
Storage requirements should be taken directly from the Tofacent package and official product documentation.
For Tofacent specifically:
Storage conditions: [Information requires verification]
Do not substitute the storage requirements of XELJANZ for Tofacent unless the products’ official documentation establishes that the same requirements apply.
Quality and Regulatory Status
The regulatory status of Tofacent is:
[Information requires verification]
The following should be independently confirmed before publication:
- Country of authorization
- Registration number
- Marketing authorization holder
- Manufacturing authorization
- Dosage form
- Strength
- Product labeling
- Good Manufacturing Practice documentation where relevant
The regulatory approval of XELJANZ does not, by itself, establish regulatory approval of Tofacent.
Medical Information Notice
Tofacent 5 mg is presented on this website for general pharmaceutical and educational information.
Tofacitinib is a prescription immunomodulatory medicine with potentially serious risks. Information on this website should not be used to diagnose a disease, determine an individualized dose or replace professional medical advice.
Patients should:
- Use tofacitinib only when prescribed or otherwise appropriately authorized.
- Follow the applicable official product information.
- Take the medicine exactly as directed.
- Discuss infections, vaccination, pregnancy, breastfeeding and other medical conditions with a healthcare professional.
- Report concerning adverse effects promptly.
- Never change treatment solely on the basis of website information.
FAQ
What is Tofacent 5 mg?
Tofacent 5 mg is identified on this website as a product containing tofacitinib 5 mg. The specific manufacturer and regulatory status require verification.
What is tofacitinib?
Tofacitinib is a small-molecule Janus kinase inhibitor used in selected immune-mediated inflammatory diseases.
What is the reference product for tofacitinib?
The established U.S. reference brand is XELJANZ, developed by Pfizer. XELJANZ received its initial U.S. approval in 2012.
Who developed tofacitinib?
Tofacitinib was discovered and developed by Pfizer.
Who manufactures Tofacent?
The specific Tofacent manufacturer is [Information requires verification]. It should not be assumed to be Pfizer.
Is Tofacent the same as XELJANZ?
Not necessarily. Both may contain tofacitinib, but product-specific formulation, manufacturing, packaging and regulatory details may differ.
What is tofacitinib used for?
Current U.S. labeling includes selected adult patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis, as well as certain pediatric patients with psoriatic arthritis or polyarticular-course juvenile idiopathic arthritis.
Is Tofacent 5 mg a JAK inhibitor?
Yes. Tofacitinib, the stated active ingredient, is a Janus kinase inhibitor.
How does tofacitinib work?
Tofacitinib inhibits JAK-mediated intracellular signaling pathways involved in immune and inflammatory responses.
What are the most important safety concerns?
Important risks include serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis.
Can tofacitinib cause blood clots?
Yes. Thrombosis, including pulmonary embolism, deep-vein thrombosis and arterial thrombosis, has been reported and is included in the boxed warning.
Can tofacitinib increase infection risk?
Yes. Tofacitinib can increase the risk of serious infections, including tuberculosis and other bacterial, fungal, viral and opportunistic infections.
Does tofacitinib require monitoring?
Yes. Depending on the patient and indication, clinicians may monitor blood counts, liver function, lipid levels, infection status and other clinical parameters.
Can Tofacent be used during pregnancy?
Pregnancy considerations require individualized medical advice. Patients who are pregnant or planning pregnancy should discuss tofacitinib treatment with their healthcare professional.
Can breastfeeding continue during treatment?
Current U.S. XELJANZ labeling advises against breastfeeding during treatment.
Can the dose be changed?
Dose changes may be appropriate in certain clinical circumstances, but they must be determined by the treating healthcare professional according to the applicable prescribing information.
What should I do if I miss a dose?
Follow the missed-dose instructions supplied with the specific product or contact a pharmacist or healthcare professional. Do not routinely take an extra dose to compensate.
Does every country approve the same uses of tofacitinib?
No. Regulatory indications and restrictions can differ by country and can change over time.
Where can Tofacent be verified?
Verification should rely on the actual packaging, official manufacturer documentation and applicable national or regional regulatory records.
Editorial and Verification Statement
This page distinguishes documented information about tofacitinib and the reference product XELJANZ from unverified product-specific information about Tofacent.
The supplied Lenvaxen website content establishes the site’s preferred editorial approach: product-specific manufacturer, authorization and regulatory information should be marked as requiring verification when supporting documentation is unavailable, rather than presented as established fact.
For Tofacent, the same standard should be applied. The documented history of Pfizer’s development of tofacitinib and XELJANZ should not be used to infer the identity of the company manufacturing Tofacent.
References
- U.S. Food and Drug Administration / DailyMed — XELJANZ/XELJANZ XR (tofacitinib) — current U.S. prescribing information, including indications, boxed warning, dosage and safety information.
- FDA — Original XELJANZ prescribing information — initial U.S. approval in 2012 and original 5 mg tablet information.
- Pfizer — FDA approval announcement for XELJANZ — documents the November 2012 FDA approval and Pfizer’s discovery and development of XELJANZ/tofacitinib.
- Pfizer — 2012 Annual Review — historical information concerning XELJANZ and Pfizer’s development program.
- Pfizer — Global regulatory history of XELJANZ — historical information concerning approvals and launches following the original U.S. approval.
Latest News
FAQs
Tofacitinib is used for selected adults with moderately to severely active rheumatoid arthritis when treatment requirements specified by applicable labeling are met. Tofacent-specific authorization should be verified separately.
Tofacitinib is used for selected adults with moderately to severely active ulcerative colitis. The appropriate dose and treatment duration depend on the indication and applicable prescribing information.
Yes. Current U.S. labeling includes tofacitinib for selected adults with active psoriatic arthritis and certain pediatric patients aged 2 years and older.
Yes. Current U.S. labeling includes tofacitinib for selected adults with active ankylosing spondylitis when specified treatment requirements are met.
Tell your healthcare professional about infections, tuberculosis exposure or history, hepatitis, other medical conditions, current medicines, supplements, vaccination history and any relevant kidney or liver problems.
Regular monitoring may be recommended during treatment. Depending on the clinical situation, monitoring can include blood counts, liver enzymes and lipid levels.
Yes. Tofacitinib dosing may need to be modified in patients with moderate or severe renal impairment. The appropriate adjustment depends on the indication and applicable product labeling.
Yes. Liver function can affect treatment decisions and dosing. Tofacitinib is not recommended in severe hepatic impairment under current U.S. labeling.
Current U.S. labeling advises avoiding live vaccines during treatment with XELJANZ/XELJANZ XR. Vaccination status should be reviewed with a healthcare professional before treatment.
Combining tofacitinib with certain biologic DMARDs or potent immunosuppressive medicines is not recommended under current U.S. labeling. Tell your healthcare professional about all medicines you take before starting treatment.